Welcome
New Home-Mid Content
WELCOME
The King's Thrombosis Centre is a leading multidisciplinary clinical and research group dedicated to the diagnosis and treatment of hypercoagulable conditions.
We are a designated Haemophilia Centre and were the first National Venous Thromboembolism (VTE) Exemplar Centre, reflecting our national leadership in the prevention and treatment of VTE. Our clinical trials unit works in partnership with industry to develop new treatments for VTE prevention and treatment.
THE FIRST REGISTRY
With the next generation of oral anticoagulants entering clinical practice, the FIRST registry will provide an important data tool to increase knowledge and improve the quality of care of patients with VTE.
King's Thrombosis Centre COVID-19 Research
Clinicians and researchers in the King’s Thrombosis Centre are completing a number of research studies relating to the COVID-19 pandemic.
Click here to view the latest publications from our centre, relating to this.
Click here to view the BBC interview with Prof Roopen Arya on thrombosis in COVID-19.
VTE EXEMPLAR CENTRE NETWORK WEBSITE
After being hosted at the King's Thrombosis Centre website since its launch in 2007, the website is now managed as part of the National VTE prevention Programme at NHS England. Click here to access the site.
Latest News
-
Anticoagulation news items. Weeks commencing 26th April & 3rd May 2021
Prior use of therapeutic anticoagulation does not protect against COVID‐19 related clinical outcomes in hospitalized patients: a propensity score‐matched cohort study British Journal of Clinical PharmacologyRetrospective Dutch study (n=1154) found…
-
Anticoagulation news items. Week commencing 12th and 19th April 2021
Announcement regarding AstraZeneca vaccine and next steps NHS EnglandThis letter which follows the updated guidance from the MHRA and the independent Joint Committee on Vaccination and Immunisation, sets out the…
-
Anticoagulation news items. Week commencing 5th April 2021
Andexanet alfa for reversing anticoagulation: Final appraisal document National Institute for Health and Care ExcellenceIn DRAFT guidance, NICE recommends andexanet alfa as an option for reversing anticoagulation from apixaban or…
